Axovant’s spectacular crash to Earth, after a soaring IPO that saw its share price hit the heady heights of $26, is likely to become a biotech cautionary tale into the future but the next twist in the tale was revealed to be it securing a new lead candidate, this time in Parkinson’s disease.
Reageer